Uni-Bio Science Group Limited (HKG:0690)

Market Cap	632.95M
Revenue (ttm)	552.98M
Net Income (ttm)	82.77M
Shares Out	5.97B
EPS (ttm)	0.01
PE Ratio	7.86
Forward PE	n/a
Dividend	0.00 (2.61%)
Ex-Dividend Date	May 28, 2025

Volume	7,370,000
Average Volume	13,969,945
Open	0.1060
Previous Close	0.1060
Day's Range	0.1040 - 0.1110
52-Week Range	0.0460 - 0.1420
Beta	-0.08
RSI	54.97
Earnings Date	Aug 29, 2025

About Uni-Bio Science Group

Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. It operates in Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products. The company provides GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat invasive a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 487
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0690

Financial Performance

In 2024, Uni-Bio Science Group's revenue was 552.98 million, an increase of 14.08% compared to the previous year's 484.72 million. Earnings were 82.77 million, an increase of 16.79%.